Drug metabolism in drug discovery and development

被引：2

作者：

Zhoupeng Zhang ^{[1
]}

Wei Tang ^{[2
]}

机构：

[1] Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Sharp & Dohme Corp

[2] Shanghai ChemPartners

来源：

ActaPharmaceuticaSinicaB | 2018年 / 8卷 / 05期

关键词：

Bioactivation; Drug discovery and development; Drug metabolism; Metabolite; Pharmacokinetics; Pharmacodynamics; Safety; Toxicity;

D O I：

暂无

中图分类号：

R91 [药物基础科学];

学科分类号：

1007 ;

摘要：

Drug metabolism as a discipline plays an important role in drug discovery and development and the effects of drug metabolism on pharmacokinetics(PK), pharmacodynamics(PD), and safety should be carefully considered. This communication provides an overview of common strategies in the area of drug metabolism for improving PK/PD and safety profiles of drug candidates; these include, but are not limited to, collaboration with medicinal chemists on structure–activity relationships(SAR) to overcome high clearance, using deuterium replacement to further optimize a lead, prodrug approaches to circumvent formulation and delivery difficulties, and addressing issues such as species differences in metabolism,drug–drug interactions(DDI) and formation of reactive metabolites.

引用

页码：721 / 732

页数：12

共 23 条

[1]

Joseph A. DiMasi,Henry G. Grabowski,Ronald W. Hansen.Innovation in the pharmaceutical industry: New estimates of R&D costs[J].Journal of Health Economics,2016

[2]

Wayne T Nicholson,Christine M Formea.Clinical Perspective on the Clinical Pharmacogenetics Implementation Consortium Updated 2014 Guidelines for CYP2D6 and Codeine[J].Clinical Chemistry,2015(2)

[3] Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu3 Selective and CNS Penetrant Negative Allosteric Modulator (NAM) [J].

Wenthur, Cody J. ;

Morrison, Ryan ;

Felts, Andrew S. ;

Smith, Katrina A. ;

Engers, Julie L. ;

Byers, Frank W. ;

Daniels, J. Scott ;

Emmitte, Kyle A. ;

Conn, P. Jeffrey ;

Lindsley, Craig W. .

JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (12) :5208-5212

[4]

Racoosin Judith A,Roberson David W,Pacanowski Michael A,Nielsen David R.New evidence about an old drug--risk with codeine after adenotonsillectomy[J].The New England journal of medicine,2013

[5] Preclinical experimental models of drug metabolism and disposition in drug discovery and development [J].

Zhang, Donglu ;

Luo, Gang ;

Ding, Xinxin ;

Lu, Chuang .

ACTA PHARMACEUTICA SINICA B, 2012, 2 (06) :549-561

[6]

Li Ying,Doss George A,Li Yan,Chen Qing,Tang Wei,Zhang Zhoupeng.In vitro bioactivation of a selective estrogen receptor modulator (2S,3R)-(+)-3-(3-hydroxyphenyl)-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-2,3-dihydro-1,4-benzoxathiin-6-ol (I) in liver microsomes: formation of adenine adducts[J].Chemical research in toxicology,2012

[7]

Graham F. Smith.Designing Drugs to Avoid Toxicity[J].Progress in Medicinal Chemistry,2011

[8]

Kazuko Inoue,Yoshihiro Shibata,Hiroyuki Takahashi,Tomoyuki Ohe,Masato Chiba,Yasuyuki Ishii.A Trapping Method for Semi-quantitative Assessment of Reactive Metabolite Formation Using[35 S]Cysteine and[14 C]Cyanide[J].Drug Metabolism and Pharmacokinetics,2009

[9] Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases Using MetaSite and LC-MS/MS Validation [J].

Trunzer, Markus ;

Faller, Bernard ;

Zimmerlin, Alfred .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (02) :329-335

[10] A quantitative high-throughput trapping assay as a measurement of potential for bioactivation [J].

Meneses-Lorente, G ;

Sakatis, MZ ;

Schulz-Utermoehl, T ;

De Nardi, C ;

Watt, AP .

ANALYTICAL BIOCHEMISTRY, 2006, 351 (02) :266-272

← 1 2 3 →